|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q63452759
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010843.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q63452759
|
|
024
|
|
|
‡a
0000-0002-5124-1811
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q63452759
|
|
100
|
0 |
|
‡a
Maria E Cabanillas
‡c
researcher
‡9
en
|
|
375
|
|
|
‡a
2
‡2
iso5218
|
|
400
|
0 |
|
‡a
Maria E Cabanillas
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Distinguishing Recurrent Thyroid Cancer from Residual Nonmalignant Thyroid Tissue Using Multiphasic Multidetector CT
|
|
670
|
|
|
‡a
Author's Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
|
|
670
|
|
|
‡a
Author's Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines
|
|
670
|
|
|
‡a
Author's Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.
|
|
670
|
|
|
‡a
Author's Imaging of Anaplastic Thyroid Carcinoma
|
|
670
|
|
|
‡a
Author's Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer
|
|
670
|
|
|
‡a
Author's Neoadjuvant selpercatinib for advanced medullary thyroid cancer
|
|
670
|
|
|
‡a
Author's Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses
|
|
670
|
|
|
‡a
Author's Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Recent advances and emerging therapies in anaplastic thyroid carcinoma
|
|
670
|
|
|
‡a
Author's Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
|
|
909
|
|
|
‡a
(orcid) 0000000251241811
‡9
1
|
|
919
|
|
|
‡a
uniquemutationpatternsinanaplasticthyroidcanceridentifiedbycomprehensivegenomicprofiling
‡A
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
‡9
1
|
|
919
|
|
|
‡a
recentadvancesandemergingtherapiesinanaplasticthyroidcarcinoma
‡A
Recent advances and emerging therapies in anaplastic thyroid carcinoma
‡9
1
|
|
919
|
|
|
‡a
prevalenceofmedicationrelatedosteonecrosisofthejawinpatientstreatedwithsequentialantiresorptivedrugssystematicreviewandmetaanalysis
‡A
Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
phase2trialofipilimumabwithstereotacticradiationtherapyformetastaticdiseaseoutcomestoxicitiesandlowdoseradiationrelatedabscopalresponses
‡A
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses
‡9
1
|
|
919
|
|
|
‡a
neoadjuvantselpercatinibforadvancedmedullarythyroidcancer
‡A
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
‡9
1
|
|
919
|
|
|
‡a
managementofthelateralneckcompartmentinpatientswithsporadicmedullarythyroidcancer
‡A
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer
‡9
1
|
|
919
|
|
|
‡a
imagingofanaplasticthyroidcarcinoma
‡A
Imaging of Anaplastic Thyroid Carcinoma
‡9
1
|
|
919
|
|
|
‡a
facilitatinganaplasticthyroidcancerspecializedtreatmentamodelforimprovingaccesstomultidisciplinarycareforpatientswithanaplasticthyroidcancer
‡A
Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.
‡9
1
|
|
919
|
|
|
‡a
endocrinesurgeryinthecoronavirusdisease2019pandemicsurgicaltriageguidelines
‡A
Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines
‡9
1
|
|
919
|
|
|
‡a
efficacyofselpercatinibinretalteredthyroidcancers
‡A
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
‡9
1
|
|
919
|
|
|
‡a
distinguishingrecurrentthyroidcancerfromresidualnonmalignantthyroidtissueusingmultiphasicmultidetectorct
‡A
Distinguishing Recurrent Thyroid Cancer from Residual Nonmalignant Thyroid Tissue Using Multiphasic Multidetector CT
‡9
1
|
|
946
|
|
|
‡a
a
‡9
1
|
|
996
|
|
|
‡2
LC|n 2003054004
|
|
996
|
|
|
‡2
ISNI|0000000118325581
|
|
996
|
|
|
‡2
BNF|14533509
|
|
996
|
|
|
‡2
ISNI|0000000036911878
|
|
996
|
|
|
‡2
DNB|1056550007
|
|
996
|
|
|
‡2
LC|no2018172910
|
|
996
|
|
|
‡2
DNB|1169842100
|
|
996
|
|
|
‡2
BNC|981061241863306706
|
|
996
|
|
|
‡2
PTBNP|1667780
|
|
996
|
|
|
‡2
LC|no 93022148
|
|
996
|
|
|
‡2
BNC|981058513248406706
|
|
996
|
|
|
‡2
LC|n 2005033420
|
|
996
|
|
|
‡2
SUDOC|086963406
|
|
996
|
|
|
‡2
ISNI|0000000041619003
|
|
996
|
|
|
‡2
ISNI|0000000040591563
|
|
996
|
|
|
‡2
BNCHL|10000000000000000799457
|
|
996
|
|
|
‡2
BNE|XX4716075
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
